TNF and ulcerative colitis: A phase III, multicenter, double-blind, placebo-controlled study of Etrolizumab, a monoclonal antibody specifically targeting the β7 subunit, in patients with moderately-to-severely active ulcerative colitis who had been previously treated with anti-TNF drugs, showed that the Etrolizumab group was able to achieve a higher rate of remission compared to the control group.